Supernus Pharmaceuticals 8-K Report: Key Insights & Stock Info (Feb 2025)

Based on the provided section of the financial report, here are the key points and insights:

Entity Information:

Company Name: Supernus Pharmaceuticals, Inc.
State of Incorporation: Delaware (DE)
CIK (Central Index Key): 0001356576
SEC File Number: 001-35518
EIN (Employer Identification Number): 20-2590184
Address: 9715 Key West Ave, Rockville, MD 20850
Contact Number: 301-838-2500

Stock Information:

Type of Stock: Common Stock
Par Value: $0.001 per share
Ticker Symbol: SUPN
Exchange: NASDAQ

Filings:

Filing Type: 8-K (Current Report)
Filing Date: February 18, 2025

Period of Report:

Start Date: February 18, 2025
End Date: February 18, 2025

XBRL Context:

The report is structured in XBRL (eXtensible Business Reporting Language), which indicates it is machine-readable and provides a standardized format for financial data.

Insights:

This report indicates that Supernus Pharmaceuticals is filing a current report (8-K) on the same day as the report's effective date, which could imply the disclosure of significant events or corporate changes.
The use of XBRL suggests a commitment to transparency and accessibility of financial information, which can enhance investor confidence.
As a publicly traded company on NASDAQ, Supernus Pharmaceuticals is subject to regulatory oversight and must comply with SEC requirements, highlighting its operational scale and public interest.

These details are essential for stakeholders, including investors, analysts, and regulators, to understand the company's current state and any immediate actions or events that could impact its performance.